Vaxcyte to Host Webcast and Conference Call to Present Topline Results from VAX-24 Infant Phase 2 Study
SAN CARLOS, Calif., March 30, 2025 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company…
37,403$
2,28%
Echtzeit-Aktienkurs Vaxcyte Inc.
Bid:
Ask:
Nachrichten zur Vaxcyte Inc. Aktie
Vaxcyte, Inc. (PCVX) Q4 2024 Earnings Call Transcript
…
Alexandria Announces Long-Term Lease at San Carlos Mega Campus
ARE announces that it has executed a 10-year lease with Vaxcyte, Inc., a clinical-stage biopharmaceutical company.…
Vaxcyte Announces Pricing of $1.3 Billion Public Offering
SAN CARLOS, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company…
Vaxcyte to Host Webcast and Conference Call to Present Topline Results from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine Candidate, in Adults Aged 50 and Older
SAN CARLOS, Calif., Sept. 02, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company…
Vaxcyte, Inc. (PCVX) Q4 2023 Earnings Call Transcript
…
Vaxcyte, Inc. (PCVX) Is Up 2.14% in One Week: What You Should Know
Does Vaxcyte, Inc. (PCVX) have what it takes to be a top stock pick for momentum investors? Lets find out.…